• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Stroke in the patient with diabetes (Part 2) – Prevention and the effects of glucose lowering therapies
There is a higher incidence of stroke in both the type 2 diabetic and the non-diabetic insulin resistant patient which is accompanied by higher morbidity and mortality. Stroke primary prevention can be achieved by controlling atrial fibrillation and hypertension, and the utilization of statins and anticoagulant therapies. Utilizing pioglitazone and GLP-1 receptor agonists reduce the risk of stroke while the utilization of metformin, α-glucosidase inhibitors, DPP-4 and SGLT-2 inhibitors have no effect.
Source: Diabetes Research and Clinical Practice - May 11, 2020 Category: Endocrinology Authors: David S.H. Bell, Edison Goncalves Tags: Review Source Type: research

Stroke in the patient with diabetes (Part 2) -Prevention and the effects of glucose lowering therapies
There is a higher incidence of stroke in both the type 2 diabetic and the non-diabetic insulin resistant patient which is accompanied by higher morbidity and mortality. Stroke primary prevention can be achieved by controlling atrial fibrillation and hypertension, and the utilization of statins and anticoagulant therapies. Utilizing pioglitazone and GLP-1 receptor agonists reduce the risk of stroke while the utilization of metformin, α-glucosidase inhibitors, DPP-4 and SGLT-2 inhibitors have no effect.
Source: Diabetes Research and Clinical Practice - May 11, 2020 Category: Endocrinology Authors: David S.H. Bell, Edison Goncalves Tags: Review Source Type: research

Rosuvastatin decreases testosterone levels but not sexual function in men with type 2 diabetes
Type 2 diabetes is often associated with hypertension and dyslipidemia. Because dyslipidemia exacerbates macrovascular disease, including coronary heart disease, stroke, and peripheral vascular disease, lipid lowering therapy is indicated for patients with type 2 diabetes, because lipid lowering therapy has been found to greatly reduce cardiovascular events in this population [1]. Statin use, however, can lead to reduced hepatic synthesis of cholesterol by inhibiting 3-hydroxy-methylglutaryl-CoA reductase.
Source: Diabetes Research and Clinical Practice - August 5, 2016 Category: Endocrinology Authors: Ching Jung Hsieh, Bin Huang Source Type: research

Effectiveness of combined therapy with angiotensin-converting enzyme inhibitors and statins in reducing mortality in diabetic patients with critical limb ischemia: An observational study
Conclusions: In patients with diabetes and CLI mortality after two years is high. Life expectancy was better in patients receiving combined therapy with ACE and statin but not with therapy with only a statin or an ACE.
Source: Diabetes Research and Clinical Practice - February 3, 2014 Category: Endocrinology Authors: Ezio Faglia, Giacomo Clerici, Alessia Scatena, Maurizio Caminiti, Vincenzo Curci, Alberto Morabito, Vincenzo Prisco, Rosaria Greco, Mike Edmonds Tags: Clinical Care and Education Source Type: research